Application
A. Western blot analysis on (1) Hela, cell lysates using anti-PKR (N-term) RabMAb (Cat. #AJ1627b), 1:5,000 dilution.Application
B. Immunohistochemical analysis of paraffin-embedded human stomach carcinoma using anti-PKR (N-term) RabMAb (Cat. #AJ1627b).Application
C. Immunofluorescent staining of HeLa cells using anti-PKR(N-term) RabMAb (Cat. #AJ1627b).| Product Name | PKR Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | EIF2AK2, PKR, PRKR, Interferon-induced, double-stranded RNA-activated protein kinase, p68 kinase;P1/eIF-2A protein kinase |
| Clonality | Monoclonal |
|---|---|
| Clone Number | YE350 |
| Host Species | Rabbit |
| Tested Applications | WBIHCIF |
| WB:1:1000~5000 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | PKR PRKR |
|---|---|
| Alternative Names | EIF2AK2 PKR PRKR Interferon-induced double-stranded RNA-activated protein kinase p68 kinase P1/eIF-2A protein kinase |
| Molecular Weight(MW) | 62094 Da |
| Function | Following activation by double-stranded RNA in the presence of ATP, the kinase becomes autophosphorylated and can catalyze the phosphorylation of the translation initiation factor EIF2S1, which leads to an inhibition of the initiation of protein synthesis. Double-stranded RNA is generated during the course of a viral infection. In addition to serine/threonine-protein kinase activity, also has tyrosine-protein kinase activity: phosphorylates CDK1 upon DNA damage. CDK1 phosphorylation triggers CDK1 polyubiquitination and subsequent proteolysis, thus leading to G2 arrest |
| Tissue Specificity | A synthetic peptide corresponding to residues following the first double-stranded RNA-binding domain of human PKR was used as immunogen. The antibody does not cross-react with other GCN2 family members. |
| Entrez Gene | 5610 |
|---|
Application
A. Western blot analysis on (1) Hela, cell lysates using anti-PKR (N-term) RabMAb (Cat. #AJ1627b), 1:5,000 dilution.
Application
B. Immunohistochemical analysis of paraffin-embedded human stomach carcinoma using anti-PKR (N-term) RabMAb (Cat. #AJ1627b).
Application
C. Immunofluorescent staining of HeLa cells using anti-PKR(N-term) RabMAb (Cat. #AJ1627b).| Application Notes | WB:1:1000~5000 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
